Current Clinical Trials

Breast Cancer Clinical Trials:

BCCR: Breast Cancer Collaborative Registry (Non-treatment study)

EA1181: (CompassHER2 pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer)

A011801: The CompassHER2 trials (COMprehensive use of Pathologic Response ASSessment to optimize therapy in HER2-positive breast cancer): CompassHER2 Residual Disease (RD), a double-blinded, phase III randomized trial of T-DM1 and placebo compared with T-DM1 and tucatinib

GYN Cancer Clinical Trials:

NRG GY026: A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma

Lung Cancer Clinical Trials:

Alliance A081801: Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)

A151216: (ALCHEMIST) Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial

ECOG E4512: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib vs. Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

LUNGMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer

Alliance A171901: Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated with First-Line MK-3475 (Pembrolizumab) +/- Chemotherapy (Oncologist’s/Patients Choice)

S1800D: A phase II/III Study of N-803 (ALT-803) Plus Pembrolizumab Versus Standard of Care in Patients with Stage IV or Recurrent Non-Small Cell Lung Cancer Previsouly Treated with Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub Study)

Supportive Care Clinical Trials:

S2013: “Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study” (NCT# 04871542)

A212102: “Blinded Reference Set for Multicancer Early Detection Blood Tests”

TCBIO-001-0710: The Caris Biorepository Research Protocol

Website for all clinical trials:

For more information about ongoing clinical trials at the William E. Kahlert Regional Cancer Center, please contact the oncology research team at 410-601-6120